AG
SWTX

Artal Group’s SpringWorks Therapeutics SWTX Stock Holding History

Artal Group’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,313,026
Closed -$49.5M – 89
2024
Q2 		$49.5M Sell
1,313,026
-102,322
-7% -$4.31M 1.26% 10
2024
Q1 		$69.7M Sell
1,415,348
-200,000
-12% -$9.25M 1.77% 8
2023
Q4 		$59M Sell
1,615,348
-201,272
-11% -$5.25M 1.96% 9
2023
Q3 		$42M Hold
1,816,620
– – 1.8% 11
2023
Q2 		$47.6M Sell
1,816,620
-729
-0% -$19.2K 1.48% 12
2023
Q1 		$46.8M Sell
1,817,349
-182,651
-9% -$5.34M 2.78% 10
2022
Q4 		$52M Sell
2,000,000
-53,403
-3% -$1.32M 2.9% 8
2022
Q3 		$58.6M Buy
2,053,403
+1,153,403
+128% +$33.1M 2.5% 9
2022
Q2 		$22.2M Buy
900,000
+50,000
+6% +$1.83M 1.18% 21
2022
Q1 		$48M Hold
850,000
– – 2.01% 14
2021
Q4 		$52.7M Buy
850,000
+250,000
+42% +$16.5M 1.43% 18
2021
Q3 		$38.1M Buy
600,000
+100,000
+20% +$7.71M 0.85% 28
2021
Q2 		$41.2M Buy
500,000
+100,000
+25% +$7.59M 0.84% 25
2021
Q1 		$29.4M Sell
400,000
-50,000
-11% -$3.92M 0.52% 45
2020
Q4 		$32.6M Buy
450,000
+165,000
+58% +$10.6M 0.7% 39
2020
Q3 		$13.6M Sell
285,000
-15,000
-5% -$639K 0.33% 67
2020
Q2 		$12.6M Sell
300,000
-50,000
-14% -$1.78M 0.35% 62
2020
Q1 		$9.45M Hold
350,000
– – 0.4% 50
2019
Q4 		$13.5M Buy
350,000
+41,474
+13% +$971K 0.52% 35
2019
Q3 		$6.69M Buy
+308,526
New +$7.29M 0.27% 63

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Artal Group's SWTX Position: Q3 2024 in Review

Artal Group sold out of SpringWorks Therapeutics (SWTX) in Q3 2024, closing a stake of 1,313,026 shares — an estimated $49.5M sold.

Artal Group first reported a position in SWTX in Q3 2019 and held it in 20 quarters. The position peaked at $69.7M in Q1 2024. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Artal Group reported no remaining SpringWorks Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,313,026 SpringWorks Therapeutics shares in Q3 2024, an estimated $49.5M.
  • Artal Group first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 20 quarters.
  • Artal Group's SpringWorks Therapeutics position peaked at $69.7M in Q1 2024.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.